Sign In
Buy TARS
$58.76
+1.35 (+2.35%)
At Close: Jun 03, 2026
Tarsus Pharmaceuticals, Inc. Appoints Dianne Whitfield as Chief Human Resources Officer
09:24am, Thursday, 07'th Jan 2021
IRVINE, Calif., Jan. 07, 2021 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), a late clinical-stage biopharmaceutical company whose mission is to discover and deliver breakthrough tre
Tarsus Pharmaceuticals, Inc. to Present at the 2021 ICR Virtual Conference
05:00pm, Tuesday, 05'th Jan 2021
IRVINE, Calif., Jan. 05, 2021 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), a late clinical-stage biopharmaceutical company whose mission is to discover and deliver breakthrough tre
Tarsus Pharmaceuticals, Inc. Announces Type C Meeting with FDA Regarding NDA Submission Requirements for Lead Candidate TP-03
07:00am, Wednesday, 23'rd Dec 2020
The Company began enrolling patients in Saturn-1 in September 2020 and expects to initiate its second pivotal registration trial, Saturn-2, in 2021 The Company began enrolling patients in Saturn-1 in
Tarsus Pharmaceuticals, Inc. Announces Inclusion in the Russell 3000® Index and Russell 2000® Index
07:00am, Monday, 21'st Dec 2020
IRVINE, Calif., Dec. 21, 2020 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), a late clinical-stage biopharmaceutical company whose mission is to discover and deliver breakthrough tre
Tarsus Pharmaceuticals, Inc. Appoints Wendy Yarno to Board of Directors
03:24pm, Thursday, 19'th Nov 2020
IRVINE, Calif., Nov. 19, 2020 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), a late clinical-stage biopharmaceutical company whose mission is to discover and deliver breakthrough tre
Tarsus Pharmaceuticals, Inc. to Present at the Jefferies Virtual London Healthcare Conference
07:35pm, Friday, 13'th Nov 2020
IRVINE, Calif., Nov. 13, 2020 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (“Tarsus” NASDAQ: TARS), a late clinical-stage biopharmaceutical company whose mission is to discover and deliver bre
